Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic

Michael C. Bellavia1,2, Ravi B. Patel1,3, and Carolyn J. Anderson2,4

1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania; 2Department of Chemistry, University of Missouri, Columbia, Missouri; 3Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania; and 4Department of Radiology, University of Missouri, Columbia, Missouri

Immune checkpoint inhibitors (ICIs) have revolutionized cancer care, but many patients with poorly immunogenic tumors fail to benefit. Preclinical studies have shown that external beam radiotherapy (EBRT) can synergize with ICI to prompt remarkable tumor regression and even eradication. However, EBRT is poorly suited to widely disseminated disease. Targeted radiopharmaceutical therapy (TRT) selectively delivers radiation to both the primary tumor and the metastatic sites, and promising results achieved with this approach have led to regulatory approval of certain agents (e.g., 177Lu-PSMA-617/Pluvicto for metastatic prostate cancer). To further improve therapeutic outcomes, combining TRT and ICI is a burgeoning research area, both preclinically and in clinical trials. Here we introduce basic TRT radiobiology and survey emerging and clinically translated TRT agents that have been combined with ICI.

Key Words: oncology: general; radiobiology; radionuclide therapy; immune checkpoint; targeted radiopharmaceutical therapy

J Nucl Med 2022; 63:1636–1641
DOI: 10.2967/jnumed.122.264373

Blocking suppressive interactions that inhibit antitumor immune activation with antibody-based immune checkpoint inhibitors (ICIs) has led to unprecedented and durable responses in patients with numerous cancer types (1). Most notable of these are antibodies to the PD-1/PD-L1 axis (programmed death receptor 1 and its ligand) and to CTLA-4 (cytotoxic T lymphocyte antigen 4), which may be used together given the nonredundant roles of these mediators in tumor immune evasion (2). However, poorly immunogenic tumors in particular may not respond to ICIs, and for those that do eventual immune escape often occurs (1,3).

In rare cases, combining external beam radiation therapy (EBRT) and ICI has prompted regression of nonirradiated metastases (the abscopal effect) in patients (4). Further, preclinical studies demonstrate that EBRT can induce responses in tumors initially refractory to ICI and improve ICI effectiveness in responsive “hot” tumors (2,5). EBRT causes accumulation of damaged DNA in the tumor cell cytosol, which prompts a type I interferon response via activation of the stimulator of interferon genes (STING) adaptor protein (6). These signals, with concurrent upregulation or secretion of damage-associated molecular patterns (e.g., high mobility group box protein 1) due to tumor cell death (7), may stimulate dendritic cells to cross-prime naïve CD8+ T cells with released tumor antigens (8). The irradiated tumor and tumor-draining lymph nodes become hubs for antigen presentation (9), leading to diversification and clonal expansion of the T-cell receptor repertoire (2). Surviving tumor cells are sensitized to immune elimination via upregulation of immune susceptibility markers (e.g., MHC-I) and the display of tumor neoantigens (10) as well as altered expression of checkpoint molecules such as PD-L1 (11). Together, these tumor microenvironment (TME) modifications increase ICI efficacy when combined with radiotherapy.

Although low-dose EBRT (2–3 Gy) can be administered safely to large fields or the whole body, it induces systemic lymphocyte depletion that may confound effective antitumor immunity (12). Also, delivering higher targeted EBRT doses to multiple small tumors or micrometastatic disease may not be feasible. Given these drawbacks, targeted radiopharmaceutical therapy (TRT), which systemically delivers radiation via a peptide, antibody, or other ligand carrier targeted to a tumor receptor or antigen, is more suitable. The radionuclide coupled to these carriers mainly decays via α- or β-particles, with or without low-energy (e.g., Auger) electrons. Radionuclide selection is largely guided by matching the decay half-life to the biologic half-life of the carrier molecule (13). As in EBRT, linear energy transfer (LET), the energy deposited per unit distance, dictates the extent of tissue and tumor penetration for TRT emissions. α-particles have a LET of 50–230 keV/μm with a tissue penetration depth of 50–100 μm, whereas β-emissions have a LET of 0.2 keV/μm with a maximum penetration depth ≈ 12 μm; Auger electrons have a LET of 4–25 keV/μm and a tissue penetration depth maximum < 1 μm (13). Radionuclides decaying by α-particles and Auger electrons may be more apt to induce cell death and phenotypic modulation in individual tumor cells if internalized (14). Yet these radionuclides may be less suited toward targeting larger tumors or may fail to modify the TME immune milieu as limited dose reaches the tumor stroma. Those with longer-range emission (e.g., β-particles) target tumor cells via crossfire radiation—emissions from TRT bound to adjacent cells (15). As such, β-particles are less likely to effectively target small tumor cell clusters or circulating tumor cells. Two peptide TRT ligands most under study in current and published clinical trials and recently approved by the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) use the β-emitter 177Lu: 177Lu-DOTATATE (Lutathera) to treat neuroendocrine tumors (NETs) and 177Lu-PSMA-617 (Pluvicto,
MC38 colorectal cancer (24). Choi et al. demonstrated in B16F10 melanoma that 177Lu-labeled LLP2A, a peptidomimetic selective to VLA-4, with dual ICI (anti-CTLA-4 and anti–PD-1 or anti–PD-L1), significantly improved survival relative to either TRT or dual ICI (22). Combining a modified RGD peptide to bind integrin αvβ3 labeled with 177Lu paired with anti-PD-L1, Chen et al. showed that concurrent administration significantly reduced tumor volume and extended survival versus a sequential approach in MC38 colorectal cancer (24). A significant drawback of peptide TRT is relatively rapid clearance from the blood, limiting tumor accumulation and response duration (25). To extend circulation lifetime, carrier PEGylation (26) and incorporation of albumin-binding moieties (24,25) have been explored.

**Antibody and Antibody Fragment**

**TRT + ICI**

Because antibodies bind with high affinity and selectivity to their epitope, in addition to their commercial availability, they have been extensively implemented for TRT (radioimmunotherapy [RIT]) (27). Maximum tumor accumulation and blood clearance is typically not achieved until 5–10 d after injection (28). As such, long-lived radioisotopes (177Lu: half-life, 6.7 d; 225Ac: half-life, 9.9 d) may be optimal to deliver a therapeutic dose. Due to the long circulation time of full-length antibodies (serum half-life of 1–3 wk (27)), nontarget tissues may receive substantial radiation doses. Alternatively, radiolabeled engineered antibody fragments (e.g., minibodies, single-domain antibodies) may be used. Antibody fragments also exhibit increased tumor penetration, albeit at the expense of lower tumor uptake due to more rapid blood clearance. However, antibody fragments of a molecular weight of <60 kDa clear primarily through the kidney, which can result in renal toxicity (27).

Jiao et al. reported notable tumor growth delay and improved survival for melanoma-bearing mice receiving an anti–melanin antibody (h8C3) labeled with the α-emitter 213Bi + anti–PD-1 relative to anti–PD-1 alone (29). In a follow-up study with longer-lived isotopes (177Lu, 225Ac) and to deduce the mechanisms involved, 225Ac-h8C3 provided no improvement with or without anti-PD-1 (30). Although low-dose 177Lu-h8C3 + anti–PD-1 significantly slowed tumor growth and improved survival, no difference was observed in tumor-infiltrating T cells versus untreated controls. A fully human anti–mesothelin antibody labeled with the α-emitter 227Th (227Th-TTC) spurred multiple immunostimulatory pathways in murine colorectal cancer expressing human mesothelin that increased CD8+ T-cell infiltration while reducing CD4+ T cells, the effects of which were augmented by anti–PD-L1 (31). Depletion of suppressive cells in the TME by β RT (177Lu-anti-CD11b) increased dual ICI (anti–CTLA-4 and anti–PD-1) efficacy in a glioma model, without other significant alterations to the TME immune cell composition (32). Others have used ICIs themselves as radioimmunotherapy agents, particularly anti–PD-L1, given its demonstrated clinical prognostic value in determining responsiveness to PD-1/L1 therapy.

**PRECLINICAL STUDIES SUGGEST SYNERGY BETWEEN TRT AND ICI**

**Peptide TRT + ICI**

Peptide-based TRT agents have been widely investigated because of their greater solid tumor penetration and lower capacity for immunogenicity relative to antibodies or antibody fragments (19). Lutathera to target somatostatin receptor subtype 2 (SSTR2) was the first peptide TRT agent to be FDA-approved in 2018. Other cell surface proteins overexpressed in malignancy and that facilitate angiogenesis (integrin αvβ3) or metastatic spread (integrin αvβ3/VLA-4) have received increased interest (20,21). Recently, pioneering peptide TRT studies directed to these targets improved therapeutic outcomes in combination with ICI in B16F10 melanoma (22,23) and both Novartis) for metastatic castration-resistant prostate cancer (mCRPC). Importantly, it has been demonstrated ex vivo that dose-equivalent β TRT can achieve STING activation comparable to that of EBRT (16), which is crucial to its translational potential in combination with ICI. However, TRT-induced alterations to antitumor immunity have only begun to be elucidated (17,18). Figure 1 shows a putative mechanism for TRT and ICI cooperation based on our understanding of EBRT-mediated effects and preliminary studies with TRT.

At present, most studies involving combined TRT and ICI have been conducted preclinically, with minimal phase I and case report data available, although numerous clinical trials are ongoing. In this review, we will discuss the recent progress of TRT + ICI therapy and future considerations to optimize clinical efficacy.

**FIGURE 1.** TRT and ICI synergize via immune mechanisms. TRT agent binds a tumor cell target receptor, and emitted radiation induces release of tumor-associated antigens and damage-associated molecular patterns (DAMPs), causes DNA damage, and potentially prompts immunogenic cell death. Damaged cytoplasmic DNA stimulates STING, leading to a type I interferon response. Tumor MHC-I expression is increased as is neoantigen display, and stimulated activation of dendritic cells (DCs) correspondingly increases antigen cross-presentation to T cells. The expression of immune checkpoint molecules is modulated, allowing for maintained immune activation with ICI. As a DAMP, calreticulin is newly expressed on the outer membrane of tumor cells undergoing immunogenic cell death (18), leading to phagocytosis by DCs that is central to their activation (7). dsDNA = double-stranded DNA; TCR = T-cell receptor. (Created with BioRender.com.)
Small-Molecule TRT + ICI

Much of the current work with small-molecule TRT involves optimizing PSMA-targeted ligands to maximize tumor uptake while diminishing toxicity. PSMA is a hallmark antigen expressed by most prostate cancers, and its upregulation is associated with castration resistance and metastasis (mCRPC) (36). PSMA-617 is the lead TRT candidate under study preclinically and was FDA-approved on March 23, 2022. Although phase III clinical results of $^{177}$Lu-PSMA-617 in mCRPC were impressive (37), from a meta-analysis, 30% of patients are refractory to β-therapy (no decline in serum prostate-specific antigen [PSA]) (38). The effectiveness of targeted α-therapy ($^{225}$Ac-PSMA-617) can vary among these patients, given the disease state (early vs. late mCRPC), the extent of pretreatment, and metastatic profile (39,40). PSA reduction with $^{225}$Ac-PSMA-617 in TRT-naïve tumors can be more substantial than that reported for $^{177}$Lu-PSMA-617, as expected given the greater LET of $^{225}$Ac (40). In a murine prostate cancer model, Czernin et al. aimed to exploit potentially increased tumor immunogenicity spurred by $^{225}$Ac-PSMA-617 by adding anti–PD-1 (41). The combination synergized to improve survival and delay time to progression, but the immune correlates were not reported.

Directing α-therapy to the tumor cell nucleus prompts extensive DNA double-strand breaks, inducing antitumor T cell activation that can be invigorated by ICI. Dabagian et al. used an $^{211}$At-labeled small-molecule inhibitor of PARP, a class of nuclear enzymes that facilitate double-strand break repair (42). With anti–PD-1 in a mouse glioblastoma model, the combination nearly doubled the mean progression-free duration of ICI (65 vs. 36 d) and led to complete response in all mice, compared with 60% of mice receiving ICI alone. Interestingly, TRT increased macrophage recruitment while depleting circulating T cells. The authors postulated that the improved therapeutic effect of the combination was due to activated macrophage proinflammatory signaling maintained by blocking PD-1.

TRT CAN SENSITIZE “COLD” TUMORS TO ICI

The key promise of TRT + ICI is the capability to render immunologically “cold” tumors (unresponsive to ICI alone) vulnerable to ICI via radiation-induced immune activation. Major cancer types resistant to ICI include colon, prostate, and breast cancer, although varied responses can occur even among tumors within the same patient (43). These tumors display minimal T-cell infiltration and substantially impaired preexisting antitumor immunity. Radiation has been shown to elicit antitumor immune responses through induction of a cGAS-STING–mediated type I interferon response, which is dose-dependent (17). From preclinical experiments, antitumor immunomodulation via EBRT occurs even at low doses (2–5 Gy) (43). This observation could be leveraged by rationally designed TRT to deliver a low dose sufficient for immunostimulation while sparing radiosensitive lymphocytes systemically.

Patel et al. recently used this approach to evaluate the alkylphosphocholine analog NM600 labeled with the β-emitter $^{90}$Y in combination with anti–CTLA-4 in multiple ICI-resistant tumor models (Fig. 2) (17). When low-dose (2.5–5 Gy) $^{90}$Y-NM600 was received by the tumor as determined from $^{86}$Y-NM600 PET via Monte Carlo dosimetry software, survival was significantly improved compared with ICI alone. Dramatic responses were observed, with up to two thirds of mice receiving the combination experiencing complete response and tumor-specific T-cell memory, compared with none in either single-treatment group. No signs of toxicity were seen. The combined treatment increased T-cell infiltration and mitigated exhaustion. Intriguingly, the authors showed that unlike a previous report using a moderate-dose, single-tumor–directed EBRT (2), low-dose TRT did not expand T-cell receptor diversity despite the clonal expansion of tumor-infiltrating T cells. By combining these modes of EBRT and TRT, their nonredundant effects better potentiated response to anti–CTLA-4, allowing for control of a secondary (received no EBRT) tumor and optimal survival relative to either TRT or EBRT + anti–CTLA-4.

CLINICAL TRIALS OF TRT + ICI

Although combination ICI + TRT clinical trials are ongoing, there are few recent reports of intentional TRT sensitization to ICI in the available clinical literature, enabled by compassionate-use authorization. Two case reports demonstrate impressive therapeutic efficacy with TRT + ICI in patients with metastatic Merkel cell carcinoma (MCC), an aggressive skin cancer, who progressed on first- (avelumab/anti–PD-L1) or second-line (ipilimumab/anti–CTLA-4 + nivolumab/anti–PD-1 + EBRT) therapies (44,45). Half of MCC patients may not respond or acquire resistance to ICI (45), yet MCC often expresses somatostatin receptors, allowing for targeting via $^{177}$Lu-DOTATATE, a modified octreotide. A patient with heavy MCC metastatic burden who received $^{177}$Lu-DOTATATE and resumed anti–PD-L1 demonstrated a response within days, with near complete response observed 1 mo after initiation (Fig. 3) (44). In a separate report, a patient receiving the related $^{177}$Lu-DOTATOC and resuming ipilimumab + nivolumab experienced partial response that was maintained through the time of the article submission (5 mo) (45). Although the GoTHAM trial (NCT04261855) to evaluate $^{177}$Lu-DOTATATE + avelumab for metastatic MCC has begun, survival data are unlikely to be available until 2024. Despite the rapid pace of TRT development, most exploratory clinical trials combining TRT and ICI use established TRT agents ($^{177}$Lu-DOTATATE, $^{177}$Lu-PSMA-617, $^{223}$RaCl$_2$). Those that are ongoing or have published results within the past 4 y are highlighted in the following sections.

$^{177}$Lu-DOTATATE (Lutathera) + ICI

$^{177}$Lu-DOTATATE is the culmination of more than 20 y of somatostatin analog development for NET treatment, with wide clinical adoption after the phase III NETTER-1 trial (NCT01578239) (46). Somatostatin receptor expression has also been identified in a minority of small-cell lung cancer (SCLC) (47). Because of its aggressiveness (5-y overall survival rate < 10%), SCLC often presents once disseminated and is ultimately refractory to chemotherapy (48). Because a subset of extensive-stage SCLC patients display durable responses to nivolumab, Kim et al. conducted a phase I trial (NCT03325816) combining $^{177}$Lu-DOTATATE and nivolumab at 2 TRT dose levels in patients with relapsed or refractory SCLC, SCLC remaining stable after first-line chemotherapy, or pulmonary NETs (48). Of the 7 patients with disease measurable by CT, one with extensive-stage SCLC showed partial response and two others with atypical carcinoid displayed stable disease. The SCLC patient who experienced partial response
showed avid tumor uptake of 68Ga-DOTATATE. However, unlike observations mainly from extrapulmonary NETs (46), the extent of 68Ga-DOTATATE uptake may not predict TRT efficacy in lung NETs/SCLC (47).

177Lu-PSMA-617 (Pluvicto) 

Approximately one third of patients do not respond to 177Lu-PSMA-617 despite extensive PSMA expression evident from PET (49). In a recent phase II trial (NCT02787005), pembrolizumab (anti–PD-1) demonstrated encouraging efficacy in pretreated, bone-predominant mCRPC (50). Prasad et al. observed a 40% PSA decline in a 90-yr-old patient with advanced mCRPC who initiated 177Lu-PSMA-617 while receiving pembrolizumab for locally advanced squamous cell carcinoma (49). To interrogate potential synergy between 177Lu-PSMA-617 and pembrolizumab, the phase Ib/II PRINCE trial (NCT03658447) was initiated. Although the study is ongoing, an interim report details a $50% PSA decline rate of near 75% among 37 patients (51). Seven of 9 patients with measurable disease exhibited partial responses. Therapy with 225Ac-PSMA-617 has shown remarkable efficacy (70% rate of PSA decline $\geq 50\%$, 29% complete response rate from 68Ga-PSMA PET) in heavily pretreated, TRT-naïve patients (40), but can be hampered by dose-limiting xerostomia (PSMA is expressed in the salivary glands) (52) which may be only partially resolvable (39,40). TRT via a PSMA-targeted antibody (J591) has circumvented this issue in patients (53), and a clinical trial to assess 225Ac-J591 + pembrolizumab (NCT04946370) is now recruiting.

**FIGURE 2.** TRT sensitizes “cold” murine tumor models to ICI. Tumor volume and survival in 4T1 breast cancer (A–C) and NXS2 neuroblastoma (D–F) in mice receiving 200 µg of CTLA-4 (C4, 3x) with or without 50 µCi (1.85 MBq) of 90Y-NM600 or saline control (vehicle only, VO) (n = 5–6 each). (Adapted with permission of (17)).

**FIGURE 3.** Dramatic improvement in a patient refractory to anti–PD-L1 (avelumab) receiving a single off-label dose of 177Lu-DOTATATE for heavily metastatic MCC and resuming avelumab. (A) Pretreatment 68Ga-DOTATATE PET/CT scan. (B) 177Lu-DOTATATE SPECT/CT scan during TRT. (C) 68Ga-DOTATATE PET/CT scan 1 mo after treatment. (Reprinted with permission of (44)).

177Lu-PSMA-617 (Pluvicto) + ICI

Approximately one third of patients do not respond to 177Lu-PSMA-617 despite extensive PSMA expression evident from PET (49). In a recent phase II trial (NCT02787005), pembrolizumab (anti–PD-1) demonstrated encouraging efficacy in pretreated, bone-predominant mCRPC (50). Prasad et al. observed a 40% PSA decline in a 90-yr-old patient with advanced mCRPC who initiated 177Lu-PSMA-617 while receiving pembrolizumab for locally advanced squamous cell carcinoma (49). To interrogate potential synergy between 177Lu-PSMA-617 and pembrolizumab, the phase Ib/II PRINCE trial (NCT03658447) was initiated. Although the study is ongoing, an interim report details a $50% PSA decline rate of near 75% among 37 patients (51). Seven of 9 patients with measurable disease exhibited partial responses. Therapy with 225Ac-PSMA-617 has shown remarkable efficacy (70% rate of PSA decline $\geq 50\%$, 29% complete response rate from 68Ga-PSMA PET) in heavily pretreated, TRT-naïve patients (40), but can be hampered by dose-limiting xerostomia (PSMA is expressed in the salivary glands) (52) which may be only partially resolvable (39,40). TRT via a PSMA-targeted antibody (J591) has circumvented this issue in patients (53), and a clinical trial to assess 225Ac-J591 + pembrolizumab (NCT04946370) is now recruiting.
**223RaCl₂ (Xofigo) + ICI**

Xofigo is nonchelated $^{223}$Ra, an $\alpha$-emitter with chemical similarity to calcium selectively trafficked to areas of increased bone stroma formation, as occurs within sclerotic or osteoblastic bone metastases (54). Most (>90%) mCRPC patients display bone metastases radiographically, and a substantial fraction of mCRPC deaths result from these metastases and their complications. Because of the short range of $\alpha$-radiation, cytotoxicity is constrained to the target region, limiting myelotoxicity. From a landmark phase III clinical trial (NCT00699751), Xofigo was demonstrated to significantly extend time to the first symptomatic skeletal event and overall survival (54).

To investigate whether $^{223}$Ra-mediated cell death potentiates pembrolizumab in intractable cancers, a phase II trial in mCRPC (NCT03093428) and a phase I/I trial in metastatic non-small-cell lung cancer (NCT03996473) patients with bone metastases are ongoing. Preliminary results from the mCRPC trial have not shown therapeutic benefit for the combination (55). A phase Ib trial of Xofigo + atezolizumab (anti–PD-L1) in mCRPC (NCT02814669) demonstrated increased toxicity without appreciable clinical benefit versus either alone (56).

**OUTLOOK**

TRT has been shown to enhance ICI in preclinical models, garnering increasing interest toward optimizing treatment strategies for clinical translation. Future preclinical work will likely involve elegant approaches to reduce off-target toxicity, such as pretargeting for RIT (28), as well as triple combinations of TRT + ICI + other immunotherapies for “cold” metastatic tumors resistant to ICI alone or with TRT. Given the distinct immunologic effects of TRT and EBRT, TRT + EBRT + ICI may be increasingly explored (17). In the clinic, $\alpha$- and $\beta$-TRT may be used in tandem to improve efficacy due to complementary emission penetration or to mitigate toxicity or resistance, as demonstrated for $^{177}$Lu$^{223}$Ac-PSMA-617 (57). Therapeutic benefit could then be improved with ICI.

To safely optimize TRT tumor dose delivery, individualized patient dosimetry will be required. Currently, TRT is given with a fixed dosing regimen regardless of the individual patient’s tumor burden or tumor uptake of the companion pretherapy PET tracer, despite evidence that more tailored therapy may improve outcomes (58). Current et al. recently reported that intrasubject variability in lesion PSMA expression and the frequency of PSMA low, medium, or high cells caused disparities in the therapeutic efficacy of PSMA-directed TRT in mouse prostate cancer models (59). TRT could treat low PSMA tumors but was most effective for extensive and homogeneous PSMA expression. As such, a fixed dosing strategy could lead to undertreatment and the selection of TRT-resistant clones. Individualized dosimetry could account for this. Patients with homogeneously high target expression could safely receive increased activity (60) and those with low or variable expression could be evaluated to predict therapeutic effect and the fraction of metastases that could be treated effectively. Individualized Monte Carlo-based dosimetry has demonstrated improved accuracy relative to standardized phantom-based methods in small patient cohorts (61). Further, this pretherapy dosimetry could reliably predict tumor or at-risk organ doses for TRT (62).

Several outstanding mechanistic questions must be resolved, requiring an increased understanding of TRT radiobiology. For example, for a particular TRT use, it is often unknown whether a threshold, mean, or maximum dose absorbed by the tumor is optimal for antitumor efficacy, or even if this applies across tumor volumes (13). Little to no study of TRT dose, dose rate, and scheduling regarding radioresistance or immune checkpoint modulation has been performed. Toward combination with ICI, concomitant administration has demonstrated improved efficacy compared with staggered schedules (24,31). However, the mechanism remains elusive. Taken together, it can be anticipated that as our understanding of TRT radiobiology grows, more efficacious and patient-specific combinatorial regimens will emerge.

**DISCLOSURE**

This work was funded by K08 CA241319 and R01 CA214018. Ravi B. Patel received support from the Hillman Cancer Center Early Career Fellowship for Innovative Cancer Research. No other potential conflict of interest relevant to this article was reported.

**REFERENCES**

15. Enger SA, Hartman T, Carlsson J, Lundqvist H. Cross-organ toxicity as occurs within sclerotic or osteoblastic bone metastases (54). Most (>90%) mCRPC patients display bone metastases radiographically, and a substantial fraction of mCRPC deaths result from these metastases and their complications. Because of the short range of $\alpha$-radiation, cytotoxicity is constrained to the target region, limiting myelotoxicity.
20. Beaino W, Nedrow JR, Anderson CJ. Evaluation of 68Ga- and 177Lu-DOTA-PEG4-LI2P2A for VLA-4-targeted PET imaging and treatment of metastatic mela-


24. Chen H, Zhao L, Fu K, et al. Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-


27. White JM, Escorcia FE, Viola NT. Perspectives on metals-based radioim-


29. Jiao R, Allen KJH, Malo ME, Rickles D, Dadachova E. Evaluating the combina-

30. Malo ME, Allen KJH, Jiao R, Frank C, Rickles D, Dadachova E. Mechanistic insights into synergy between melanin-targeting radioimmunotherapy and immu-


32. Foster A, Nigam S, Tatum DS, et al. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in gli-

33. Gandini S, Massi D, Mandal

34. Lejeune P, Cruciani V, Berg-Larsen A, et al. Immunostimulatory effects of targeted thortum-227 conjugates as single agent and in combination with anti-PD-L1 ther-

35. Jiao R, Allen KJH, Malo ME, Rickles D, Dadachova E. Evaluating the combina-

36. Jiao R, Allen KJH, Malo ME, Rickles D, Dadachova E. Mechanistic insights into synergy between melanin-targeting radioimmunotherapy and immu-


39. Jiao R, Allen KJH, Malo ME, Rickles D, Dadachova E. Evaluating the combina-

40. Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of overall and disease-


44. Kasi PM, Sharma A, Jain MK. Expanding the indication for novel theranost-


51. Sandhu SK. ESMO 2021: PRINCE: interim analysis of the phase Ib study of 177Lu-


55. Sandhu SK. ESMO 2021: PRINCE: interim analysis of the phase Ib study of 177Lu-